Ashley Yeo is attached to the medtech titles within Informa’s Pharma intelligence division.
As Health Care editor on In Vivo (monthly hardcopy and online daily services), he writes and commissions news and feature material to meet the strategic business and market access information needs of senior players and device makers as they move innovations into the global medtech market place.
As part of the Principal Analyst team, he also contributes news delivery and insight needs across the group’s other medtech titles in the field of market access (global regulatory, reimbursement, policy changes). Key areas of focus are Germany, the UK and global themes, and EU and other outside global regulatory insight.
A linguist by training, he joined what was later to become Informa in mid-1988 as a French and German news reporter (with some other European languages also in the mix), and has been editor of three of the group’s titles (including Clinica) over a 14-year-period.
These duties are combined with supporting the growing Ask The Analyst service. He says: “This helps us as a group keep a close relationship with long-term and potential subscribers in a sector where insight and knowledge are key to our clients’ commercial success.”
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Ashley Yeo
The probability of a postponed entry-in-force of the single Eurasian Economic Union system of medtech regulation has increased over the course of this year, according to speakers at the 2018 Informa KNect 365 Medtech Summit. But the drive for stronger local medtech industries continues, leaving foreign manufacturers with market-access problems to address.
Digital tools and maximizing the data derived from them will influence the delivery of health care in ways and to extents yet unknown. Andrew Davies, market access director for UK industry group ABHI, explains the industry's planning around this, and calls for a rethink on innovation market access structures, which are still failing to meet industry's needs.
Mid-size orthopedic implants group Corin is back in the public eye after its recent purchase by a Permira-funded group. Now ready to embark on the next chapter of its development globally, it has a clear growth plan and a firm strategic line on both what it will and will not do as a business.
The National Health Service (NHS) came into being in the UK 70 years ago today, and to mark the occasion, NHS England and UK diagnostics stakeholders have officially launched a new prevention initiative: the UK AMR Diagnostic Collaborative. Its targeted actions and recommendations will help the NHS – and global systems – tackle the ever-larger-looming issue of antimicrobial resistance.
Investment in advanced in vitro diagnostics is increasing as the technologies themselves are becoming less esoteric and more easily "understood" by patients and providers alike. Are these technologies finally breaking through the glass ceiling to visibly assume their rightful place in health care delivery?
The UK Department of Health's new system of medical device procurement for the NHS went live in May. What was the Future Operating Model (FOM) is now simply the "Operating Model." But there are yet to be any tenders under a system that supposedly champions value and total ownership. UK industry wants to believe it, but will it happen? And will Brexit get in the way?